XERS
Xeris BiopharmaBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The post-earnings company release was clearly constructive: revenue grew 38% year over year, Recorlev was the main driver, gross margin improved to 87%, and Xeris produced positive net income and adjusted EBITDA while lifting the low end of 2026 revenue guidance [#8-K-2026-05-07]. Pre-print third-party estimate pages in the packet indicated revenue expectations around $80 million and roughly breakeven EPS, so the reported $83.1 million and $0.01 GAAP EPS suggest at least a modest beat versus low external expectations.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +6.0.
What can break
Balance-sheet flexibility is better than in earlier periods, but Xeris still carried about $221.2 million of long-term debt against $111.8 million of cash at March 31, 2026, which keeps financing and execution discipline relevant [#8-K-2026-05-07].
Momentum
36
Value
59
Sentiment
81
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.80 · Bull $10.50 · Bear $5.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $11.14
Why
Momentum36 · Δ7d +0.9
Value59 · Δ7d +0.1
Sentiment81 · Δ7d +6.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
36
34% active weight
Current posture
7d trendFlat
Δ7d
+0.9
Δ21d
+0.4
Value
59
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.4
Sentiment
81
33% active weight
Current posture
7d trendImproving
Δ7d
+6.0
Δ21d
+13.2
Why this grade
Composite grade B. Momentum 36.5 / Value 58.7 / Sentiment 81.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.04B
Beta
0.64
Shares Out
165.92M
P/E (TTM) · Derived
1836.2
P/S (TTM)
4.42
P/FCF (TTM)
117.94
Rev YoY
+37.1%
EPS YoY
+103.3%
Gross Margin
+84.6%
Op Margin
+3.7%
Net Debt
$160.49M
Current Ratio
1.93
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology